Gilead Signs an Exclusive License Agreement with Rockefeller University for its Portfolio of HIV Abs

Gilead Sciences Receives the US FDA Advisory Committee’s Recommendation on Approval of Descovy for PrEP


  • Rockfeller to receive up front, milestones plus royalties on sales and will retain rights to perform non-clinical and early-stage clinical research on the portfolio of HIV Abs. Gilead to get exclusive rights to develop and commercialize Rockefeller’s full portfolio of HIV bNAbs
  • The focus of the agreement is to enhance Gilead’s HIV pipeline and will advance academic programs into potential future products
  • 3BNC117 and 10-1074 are clinical-stage products with the ability to be used as HIV long-acting therapies for treatment and prevention

Click here to read full press release/ article | Ref: Gilead | Image: Twitter